Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | KAT7 | O95251 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27086084 | 0.88 | ALDH1A1 (0.37) | GAAGPBAR1ALDH1A1 | |
| SCHEMBL30825489 | 0.85 | KAT6A (0.40) | GPBAR1KAT6AKAT8KAT7 | |
| SCHEMBL30349062 | 0.84 | GPBAR1 (0.41) | GAAGPBAR1AAK1P2RX3 | |
| SCHEMBL29920199 | 0.74 | GPBAR1 (0.39) | GAAGPBAR1KAT6AKAT8AAK1 | |
| SCHEMBL30825425 | 0.74 | GPBAR1 (0.39) | GAAGPBAR1KAT6AKAT8AAK1 | |
| SCHEMBL30825419 | 0.73 | GPBAR1 (0.38) | GPBAR1AAK1P2RX3 | |
| SCHEMBL29919993 | 0.73 | GPBAR1 (0.38) | GPBAR1AAK1P2RX3 | |
| SCHEMBL30373155 | 0.72 | GAA (0.35) | GAAGPBAR1ALDH1A1AAK1P2RX3 | |
| SCHEMBL24820699 | 0.69 | ALDH1A1 (0.47) | GAAALDH1A1RAB9A | |
| SCHEMBL3629295 | 0.68 | P2RX3 (0.32) | GAAALDH1A1AAK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022217276-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | GAA 792/4885GPBAR1 2155/4885ALDH1A1 4641/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | GAA 792/4885GPBAR1 2155/4885ALDH1A1 4641/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | GAA 792/4885GPBAR1 2155/4885ALDH1A1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.